FiercePharma1d
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
GlobalData on MSN4d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...
Antibody Drug Conjugates Market Outlook 2025-2035, with Forecasts for Payload Type, Linker Type, Target Antigen and Applications
The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...
Hosted on MSN1d
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight
The NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical ...
Zacks.com on MSN2d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...
PipelineReview.com17h
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
TOKYO, Japan & BASKING RIDGE, NJ, USA I January 17, 2055 I DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of ...
Le Lézard5d
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
Schrödinger, Inc. today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. "We are very proud of our accomplishments in 2024. We advanced ...
Le Lézard5d
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...
MM&M5d
Obesity meds to lead charge as pharma sales ride ‘momentum’ into 2025
While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...
pharmaphorum5d
Update: Daiichi Sankyo says Plexxikon R&D unit will close down
The rest of Plexxikon's pipeline is in early clinical or preclinical ... Pharmaphorum reached out to Daiichi Sankyo to ask for details about the fate of the programmes and Plexxikon's 60-strong ...